The Food and Drug Administration (FDA) issued Amendment 1 to its Request for Information (RFI) no. FDA-RFI-2026-131587 for a Commercial Off-the-Shelf (COTS) Task Management Tool (TMT). This amendment provides answers to vendor questions and extends the response due date to November 20, 2025, at 5 PM EST. The FDA seeks a TMT to streamline recurring tasks and workflows, aiming for 60% of process tasks to be templated and full staff adoption. Key requirements include ease of use, ability to handle high visibility tasks like Congressional Inquiries, and integration with existing systems. The FDA prefers a FedRAMP Moderate SaaS solution, enterprise-wide pricing, and minimal customization. The initial pilot will involve the FDA ExecSec office, with a goal of agency-wide implementation and potential future adoption by HHS. The FDA anticipates replacing spreadsheets, power apps, and an Appian tool, and integrating with its in-house AI tool, Elsa.
The FDA has issued a Request for Information (RFI) for a Commercial Off-the-Shelf (COTS) Task Management Tool (TMT). The RFI aims to gather technical and business information from the marketplace to identify potential solutions for enterprise-wide task management. The FDA seeks a TMT to support its approximately 20,000 federal and contractor staff in managing thousands of requests and inquiries. Key objectives include identifying vendors, evaluating scalability and security, analyzing the total cost of ownership, and understanding how tools can support effective task management with minimum effort and cost. The RFI details extensive functional and non-functional requirements, including advanced task creation, configurable workflows, collaboration, reporting, granular user management, audit trails, digital certificates, advanced search, AI-powered content generation, template standardization, various task views, intake and form management, external collaboration, data security, usability, performance, internal configuration, platform integration, training, specialized compliance, document management, cost flexibility, and rapid deployment. The FDA is also interested in market intelligence, performance measurement, and applicability of the Buy American Act. Responses are due by November 15, 2025.